

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SinoMab BioScience Limited

中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 3681)

**VOLUNTARY ANNOUNCEMENT
IND APPROVAL FOR SN1011 BY NMPA**

Reference is made to the announcements of SinoMab BioScience Limited (中國抗體製藥有限公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) on 14 November 2019, 29 January 2020, 29 June 2020, 1 September 2020, 15 January 2021, 24 June 2021, 23 July 2021, 7 February 2022, 20 April 2022 and 9 June 2022 in relation to the latest research and development progress of one of the Group’s key products, SN1011.

The board of directors (the “**Board**”) of the Company is pleased to announce that on 22 August 2022, an Investigational New Drug application (“**IND**”, for neuromyelitis optica spectrum disorder (“**NMOSD**”)) for SN1011 was approved by National Medical Products Administration of China (the “**NMPA**”). The IND approval would enable the Company to initiate the Phase II/III clinical study to evaluate the efficacy and safety of SN1011 in patients with NMOSD in China. The planned first patient enrollment is in the first quarter of 2023.

SN1011 is the Company’s third generation, covalent reversible BTK inhibitor designed to exhibit high selectivity with prolonged but controlled drug exposure to achieve superior efficacy and good safety profile for the long-term treatment of systemic lupus erythematosus, pemphigus, multiple sclerosis, and other rheumatology or neuro-immunological diseases. SN1011 differentiates from existing BTK inhibitors currently available in the market, such as Ibrutinib, in terms of mechanism of action, affinity, selectivity and safety. SN1011 had obtained four IND approvals (for systemic lupus erythematosus (SLE), pemphigus, multiple sclerosis (MS) and NMOSD) from the NMPA.

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG

Executive Director, Chairman and Chief Executive Officer

Hong Kong, 23 August 2022

As at the date of this announcement, the executive director of the Company is Dr. Shui On LEUNG, the non-executive directors of the Company are Dr. Haigang CHEN, Mr. Xun DONG, Ms. Wenyi LIU, Ms. Jie LIU and Mr. Lei SHI, and the independent non-executive directors of the Company are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.